Canaccord analyst William Plovanic lowered the firm’s price target on Boston Scientific (BSX) to $109 from $112 and keeps a Buy rating on the shares. The firm updated its model and estimates to reflect the business organizational changes. Additionally, they are updating our estimates to reflect management commentary during and after the earnings call.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- IHI, IHE, ARKG: Specialty Healthcare ETFs Can Help Boost a Portfolio
- Boston Scientific: Multi-Year Double-Digit Growth Outlook Makes Share Pullback a Buy Opportunity
- Boston Scientific: Durable Growth, Expanding EP Opportunity, and Upside-Skewed Valuation Justify Buy Rating
- Boston Scientific price target lowered to $112 from $130 at Bernstein
- Boston Scientific’s (BSX) Earnings Implosion Sparks Bullish Options Trade